Q1 2022 EPS Estimates for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reduced by Jefferies Financial Group

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARSGet Rating) – Analysts at Jefferies Financial Group reduced their Q1 2022 earnings estimates for shares of Tarsus Pharmaceuticals in a research note issued to investors on Tuesday, May 3rd. Jefferies Financial Group analyst F. Pinal now forecasts that the company will earn ($1.45) per share for the quarter, down from their prior estimate of ($1.44). Jefferies Financial Group also issued estimates for Tarsus Pharmaceuticals’ Q2 2022 earnings at ($1.38) EPS, Q3 2022 earnings at ($0.99) EPS, Q4 2022 earnings at ($1.05) EPS, FY2022 earnings at ($4.81) EPS, FY2023 earnings at ($4.90) EPS, FY2024 earnings at ($3.72) EPS, FY2025 earnings at $0.20 EPS and FY2026 earnings at $3.88 EPS.

Tarsus Pharmaceuticals (NASDAQ:TARSGet Rating) last posted its quarterly earnings results on Monday, March 14th. The company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.77) by $0.05. The company had revenue of $0.34 million for the quarter, compared to the consensus estimate of $7.11 million. Tarsus Pharmaceuticals had a negative return on equity of 7.66% and a negative net margin of 24.25%.

Other analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $40.00 price target on shares of Tarsus Pharmaceuticals in a research note on Tuesday. Oppenheimer upped their price objective on Tarsus Pharmaceuticals from $55.00 to $66.00 in a research report on Monday. Finally, Zacks Investment Research raised shares of Tarsus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, February 24th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $48.00.

Tarsus Pharmaceuticals stock opened at $12.05 on Friday. Tarsus Pharmaceuticals has a one year low of $11.76 and a one year high of $39.08. The business’s fifty day moving average is $17.81 and its 200 day moving average is $21.17.

In related news, major shareholder Vivo Capital Ix, Llc sold 19,738 shares of Tarsus Pharmaceuticals stock in a transaction on Wednesday, May 4th. The shares were sold at an average price of $12.67, for a total transaction of $250,080.46. Following the transaction, the insider now owns 2,474,375 shares in the company, valued at approximately $31,350,331.25. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 33.08% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of TARS. Morgan Stanley bought a new stake in Tarsus Pharmaceuticals in the 2nd quarter worth approximately $241,000. SG Americas Securities LLC raised its position in Tarsus Pharmaceuticals by 101.3% during the third quarter. SG Americas Securities LLC now owns 46,253 shares of the company’s stock valued at $997,000 after purchasing an additional 23,276 shares during the period. BlackRock Inc. lifted its stake in shares of Tarsus Pharmaceuticals by 0.7% in the 3rd quarter. BlackRock Inc. now owns 441,620 shares of the company’s stock valued at $9,519,000 after purchasing an additional 3,264 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Tarsus Pharmaceuticals by 13.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 24,523 shares of the company’s stock worth $529,000 after purchasing an additional 2,950 shares during the period. Finally, Allspring Global Investments Holdings LLC bought a new position in Tarsus Pharmaceuticals during the fourth quarter valued at $289,000. 70.00% of the stock is currently owned by institutional investors.

Tarsus Pharmaceuticals Company Profile (Get Rating)

Tarsus Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Read More

Earnings History and Estimates for Tarsus Pharmaceuticals (NASDAQ:TARS)

Receive News & Ratings for Tarsus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tarsus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.